Not available
Quote | NuCana plc (NASDAQ:NCNA)
Last: | $2.7965 |
---|---|
Change Percent: | -2.91% |
Open: | $2.83 |
Close: | $2.7965 |
High: | $2.93 |
Low: | $2.7032 |
Volume: | 15,927 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
News | NuCana plc (NASDAQ:NCNA)
NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies Global Healthcare Conference. Event: Jefferies Global Healthca...
EDINBURGH, United Kingdom, May 21, 2024 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present at TD Cowen’s 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA. Ev...
Message Board Posts | NuCana plc (NASDAQ:NCNA)
Subject | By | Source | When |
---|---|---|---|
I think we see $4 soon enough. By | bandit007 | investorshub | 07/25/2022 11:14:12 PM |
Agreed. GL | bandit007 | investorshub | 07/25/2022 11:10:50 PM |
This one is a no brainer. | Sociocobb | investorshub | 07/25/2022 7:57:05 PM |
Loaded heavy end of day. Looking forward to | bandit007 | investorshub | 07/25/2022 7:55:34 PM |
Undervalued even after the massive gains this month. | Sociocobb | investorshub | 07/18/2022 9:42:16 PM |
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies Global Healthcare Conference. Event: Jefferies Global Healthca...
EDINBURGH, United Kingdom, May 21, 2024 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present at TD Cowen’s 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA. Ev...
Key Data Readouts on Track for All Programs in 2024 Randomized Phase 2 Study of 182 Second-Line Colorectal Cancer Patients Fully Enrolled NUC-7738 plus Pembrolizumab Demonstrated Encouraging Anti-Cancer Activity in Several Patients who were Resistant to PD-1 Inhibitors ...